Our Clinical Advisory Board

Our 23-strong team boasts deep experience in RNA biology, bioinformatics analytics, neuro-translation and development.

Dr Irina Antonijevic

Chair

Experienced clinician and drug development leader, widely recognized for her leadership in advancing innovative therapies from early development through clinical stages, particularly in areas with high unmet medical needs such as neurodegenerative and psychiatric disorders.
Currently serving as Chief Medical Officer at Trace Neuroscience
Dr. Antonijevic is a board-certified physician trained in both psychiatry and neurology, with deep expertise in translational medicine and clinical development strategies

Cardiff University

Professor of Clinical Neuroscience at Cardiff University and an Honorary Consultant Neurologist at the University Hospital of Wales, leading the South Wales clinical service for Huntington’s disease.
She co-leads the Cardiff University Brain Repair Group, a multidisciplinary research team focused on developing cell-based and regenerative therapies for neurodegenerative diseases.
Dr. Rosser previously served as Chair of the European Huntington’s Disease Network (EHDN) and is currently Chair of the Scientific Committee of the Lister Institute of Preventive Medicine.

University of Iowa

Professor of Psychiatry and Biostatistics at the University of Iowa Health Care / Carver College of Medicine applying statistical modeling to neurodegenerative diseases, with a special emphasis on Huntington’s disease.
He develops and refines disease progression indexes, critical for understanding natural disease trajectories and planning clinical trials.
Dr Long also serves as Lead Biostatistician for NIH-funded longitudinal studies, such as REDICT-HD, and plays a key role as Head Biostatistician in the Data Coordinating Center of the NeuroNEXT clinical trials network.

George Huntington Institute

Founding Director and Chief Executive Officer of the George-Huntington-Institute (GHI) in Münster, Germany, a private research institute devoted to clinical care and research in Huntington’s disease. Under his leadership, the Institute participates in key Huntington’s observational studies including ENROLL-HD and clinical trials exploring disease-modifying therapies and gene therapy approaches.
Dr. Reilmann is a board-certified neurologist, widely recognized for his commitment to improving trial outcomes, patient care, and global collaboration in Huntington’s research.

University of Cambridge

Professor of Clinical Neuroscience at the University of Cambridge and Honorary Consultant Neurologist at Addenbrooke’s Hospital, Cambridge.
Serving as Lead Academic Scientist for the Alzheimer’s Research UK Drug Discovery Institute in Cambridge and Lead Consultant for the East of England Huntington’s Disease Service. His research focuses on clinical characterization of neurodegenerative disorders and the development of new therapeutic approaches, especially cell- and gene-based treatments.
Dr. Barker has led and coordinated major research programmes, including European projects and stem cell trials for Parkinson's disease as well as a range of trials in Huntington's disease.

University College London

Professor of Clinical Neurology at University College London, internationally recognised for her research in neurodegenerative diseases, particularly Huntington’s disease.
Holding several prestigious roles across UCL’s neuroscience community and the UK's top clinical research institutions recognised with many major awards. Her work has transformed the Huntington’s field, establishing frameworks for disease staging, biomarker development, and therapeutic trials that serve as models for other neurodegenerative conditions.
Dr. Tabrizi’s bench-to-bedside approach integrates deep biological insight with clinical trials to bring hope to patients with previously untreatable conditions.

Cardiff University

Professor of Functional Neurosurgery at Cardiff University and Honorary Consultant Neurosurgeon at the University Hospital of Wales.
He brings dual expertise in clinical neurosurgery and neuroscience research, especially focused on disorders like epilepsy, Parkinson’s disease, Huntington’s disease, and frontotemporal dementia. He serves as Director of the Advanced NeuroTherapies Centre (ANTC), developing and delivering emerging therapies directly to the brain, is the Academic Lead in Neurosurgery in Wales, and Head of the Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit. Dr. Gray is the UK Chief Investigator for the uniQure AMT-130 gene therapy trial in Huntington’s disease and Principal Investigator for gene therapy trials in frontotemporal dementia and Parkinson’s disease.
He also co-leads the European Huntington’s Disease Network ATMP Working Group and chairs its Surgical Delivery Task Force.

Huntington's Disease

ALS and Alzheimer's

February 2026

October 2025

June 2025

February 2025